Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026.
Sagimet Biosciences Inc. (SGMT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Balyasny Asset Management Dmitry Balyasny | 3,626,113 | $28,029,853 | 0.03% | |
| 2. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,000,652 | $23,195,040 | +200% | 0.07% |
| 3. | SilverArc Capital Devesh Gandhi | 2,927,698 | $22,631,106 | 2.35% | |
| 4. | Caligan Partners David Johnson | 2,500,000 | $19,325,000 | 0.91% | |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,500,000 | $19,325,000 | 0.49% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.27 | 12,100 | $63,730.70 | 639,200 | 2024-03-26 | Filing | |
| $4.10 | 1,600 | $6,560.00 | 627,100 | 2023-12-07 | Filing | |
| $2.35 | 590 | $1,386.50 | 590 | 2023-11-16 | Filing | |
| $16.00 | 30,000 | $480,000.00 | 3,850,275 | 2023-07-18 | Filing | |
| $16.00 | 46,875 | $750,000.00 | 46,875 | 2023-07-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.23 | 350,987 | $3,591,579.77 | 62,161 | 2026-08-14 | Filing | |
| $9.95 | 20,206 | $201,146.69 | 62,161 | 2026-08-11 | Filing | |
| $7.76 | 64,051 | $497,067.79 | 741,570 | 2026-07-20 | Filing | |
| $7.76 | 10,545 | $81,832.36 | 224,414 | 2026-07-20 | Filing | |
| $7.46 | 18,844 | $140,529.13 | 62,161 | 2026-07-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 62,477 | $617,273 | 0.03% | |
| 2. | 19,737 | $195,002 | 0.01% | |
| 3. | 17,350 | $171,418 | 0.03% | |
| 4. | 10,700 | $105,716 | 0.1% | |
| 5. | 11,238 | $104,851 | 0.01% |
News See All
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results
Sagimet Biosciences Inc. (NASDAQ:SGMT) earns a place on our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, 91% of analysts remain bullish on Sagimet Biosciences Inc.
Top 10 Stocks Under $5 That Could Triple
In this piece, we discuss the Top 10 Stocks Under $5 That Could Triple.
10 Best Get Rich Quick Stocks To Invest In
In this article, we’re going to list the 10 best get rich quick stocks to invest in.
10 Hot Penny Stocks to Buy Now
In this article, we will look at the 10 Hot Penny Stocks to Buy Now.
10 Recent IPOs in Micro Cap Stocks
In this piece, we will take a look at ten recent IPOs in micro cap stocks. There are a variety of benefits and drawbacks to listing a firm's equity for trading on the stock market.
Hedge Fund Resource Center